Expression of concern: Antisense oligodeoxynucleotides for urokinase-plasminogen activator receptor have anti-invasive and anti-proliferative effectsin vitro and inhibit spontaneous metastases of human melanoma in mice (International Journal of Cancer, (2004), 110, 1, (125-133), 10.1002/ijc.20077);Antisense oligodeoxynucleotides for urokinase-plasminogen activator receptor have anti-invasive and anti-proliferative effects in vitro and inhibit spontaneous metastases of human melanoma in mice

International Journal of Cancer

Volumn 110, Issue 1, 2004, Pages 125-133

  D'Alessio, Silvia ^a   Margheri, Francesca ^a   Pucci, Marco ^a   Del Rosso, Angela ^a   Monia, Brett P ^b   Bologna, Mauro ^c   Leonetti, Carlo ^d   Scarsella, Marco ^d   Zupi, Gabriella ^d   Fibbi, Gabriella ^a   Del Rosso, Mario ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b ISIS PHARMACEUTICALS   (United States)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Antisense oligonucleotides; ERK; Melanoma; Metastasis; Urokinase receptor (CD87)

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; UROKINASE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INVASION; CELL COUNT; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG TARGETING; ENZYME ACTIVATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LUNG METASTASIS; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

EID: 11144358203     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.33526     Document Type: Erratum

References (35)

1. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000;57:25-40.
2. Mignatti P, Rifkin DB. Nonenzymatic interactions between proteinases and the cell surface: novel roles in normal and malignant cell physiology. Adv Cancer Res 2000;78:103-57.
3. Del Rosso M, Fibbi G, Pucci M, D'Alessio S, Del Rosso A, Magnelli L, Chiarugi V. Multiple pathways of cell invasion are regulated by multiple families of serine proteases. Clin Exp Metastasis 2002;19:193-207.
4. Aguirre Ghiso JA, Kovalski K, Ossowski L. Tumor dormancy induced by down-regulation of urokinase receptor in human carcinoma involves integrin and MAPK signalling. J Cell Biol 1999;147:89-104.
5. Liu D, Aguirre Ghiso JA, Estrada Y, Ossowski L. EGFR is a transducer of the urokinase receptor initiated signal which is required for in vivo growth of a human carcinoma. Cancer Cell 2002;1:445-57.
6. Aguirre Ghiso JA. Inhibition of FAK signalling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo. Oncogene 2002;21:2513-24.
7. Aguirre Ghiso JA, Liu D, Mignatti A, Kovalski K, Ossowski L. Urokinase receptor and fibronectin regulate the ERK (MAPK) to p38 (MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 2001;12:863-79.
8. Tamm I, Dorken B, Hartman G. Antisense therapy in oncology: new hope for an old idea? Lancet 2001;358:489-97.
9. Quattrone A, Fibbi G, Anichini E, Pucci M, Zamperini A, Capaccioli S, Del Rosso M. Reversion of the invasive phenotype of transformed human fibroblasts by anti-messenger oligonucleotide inhibition of urokinase receptor gene expression. Cancer Res 1995;55:90-5.
10. Jensen F, Koprowsk, H, Pagano JS, Ponten J, Ravdin RG. Autologous and homologous implantation of human cells transformed by simian virus 40. J Natl Cancer Inst 1964;32:917-37.
11. Fibbi G, Caldini R, Chevanne M, Pucci M, Schiamone N, Morbidelli L, Parenti A, Granger HJ, Del Rosso M, Ziche M. Urokinase-dependent angiogenesis in vitro and diacylglycerol production are blocked by antisense oligonicleotides against the urokinase receptor. Lab Invest 1998;78:1109-19.
12. Fibbi, G, Pucci M, Grappone C, Pellegrini G, Salzano R, Casini A, Milani S, Del Rosso M. Functions of the fibrinolytic system in human Ito cells and its control by basic fibroblast and platelet-derived growth factor. Hepatology 1999:29:868-78.
13. Fibbi G, Barletta E, Dini G, Del Rosso A, Pucci M, Cerletti M, Del Rosso M. Cell invasion is affected by differential expression of the urokinase plasminogen activator/urokinase plasminogen activator receptor system in muscle satellite cells from normal and dystrophic patients. Lab Invest 2001;81:27-39.
14. Roldan AL, Cubellis MV, Masucci MT, Behrend N, Lund LR, Dano K, Appella E, Blasi F. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell-surface plasmin-dependent proteolysis. EMBO J 1990;9:467-74.
15. Leonetti C, D'Agnano I, Lozupone F, Valentini A, Geiser T, Zon G, Calabretta B, Citro GC, Zupi G. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice. J Natl Cancer Inst 1996;88:419-29.
16. Kjoller L, Hall A. Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J Cell Biol 2001;152:1145-1157.
17. Kjoller L. The urokinase plasminogen activator receptor in the regulation of the actin cytoskeleton and cell motility. Biol Chem 2002;383:5-19.
18. de Vries TJ, Quax PH, Denijn M, Verrijp KN, Verheijen JH, Verspaget HW, Weidle UH, Ruiter DJ, van Muijen GN. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 1994;144:70-81.
19. Ferrier CM, Van Geloof WL, Straatman H, Van De Molengraft FJ, Van Muijen GN, Ruiter DJ. Spitz naevi may express components of the plasminogen activation system. J Pathol 2002;198:92-99.
20. Stabuc B, Markovic J, Bartenjev I, Vrhovec I, Medved U, Kocijancic B. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma. Oncol Rep 2003;10:635-39.
21. May AE, Schmidt R, Kanse SM, Chavakis T, Stephens RW, Schomig A, Preissner KT, Neumann F-J. Urokinase receptor surface expression regulates monocyte adhesion in acute myocardial infarction. Blood 2002;100:3611-17.
22. Citro G, D'Agnano I, Leonetti C, Perini R, Bucci B, Zon G, Calabretta B, Zupi G. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice. Cancer Res 1998;58:283-89.
23. Leonetti C, Biroccio A, Benassi B, Stringaro A, Stoppacciaro A, Semple SC, Zupi G. Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line. Cancer Gene Ther 2001;8:459-68.
24. Koopman JL, Slomp J, de Bart ACW, Quax PHA, Verheijen JH. Mitogenic effect of urokinase on melanoma cells are independent of high affinity binding to the urokinase receptor. J Biol Chem 1998;273:33267-72.
25. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERKmapk activity as a determinant of tumor growth and dormancy; regulation by p38SAPK. Cancer Res 2003;63:1684-95.
26. Korabiowska M, Betke H, Kellner S, Stachura J, Schauer A. Differential expression of growth arrest, DNA damage genes and tumor suppressor gene p53 in nevi and malignant melanomas. Anticancer Res 1997;17:3697-3700.
27. Korabiowska M, Brinck U, Kotthaus I, Berger H, Droese M. Comparative study of the expression of DNA mismatch repair genes, the adenomatous polyposis coli gene and growth arrest DNA damage genes in melanoma recurrences and metastases. Melanoma Res 2000;10:537-44.
28. Del Rosso M, Fibbi G, Pucci M, Matucci Cerinic M. Antisense oligonucleotides against the urokinase receptor: a therapeutic strategy for the control of cell invasion in rheumatoid arthritis and cancer. Clin Exp Rheumatol 1998;16:389-93
29. Rabbani SA, Desjardins J, Bell AW, Banville D, Mazar A, Henkin J, Goldtzman, D. An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem Biophys Res Commun 1990;173:1058-64.
30. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli, F. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 1996;15:1572-82.
31. Anichini E, Zamperini A, Chevanne M, Caldini R, Pucci M, Fibbi G, Del Rosso M. Interaction of urokinase-type plasminogen activator with its receptor rapidly induces activation of glucose transporters. Biochemistry 1997;36:3076-83.
32. Shetty S, Kumar A, Johnson AR, Idell S. Regulation of mesothelial cell mitogenesis by antisense oligonucleotides for the urokinase receptor. Antisense Res Dev 1995;5:307-14.
33. Kook YH, Adamski J, Zelent A, Ossowski L. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J 1994;13:3983-91.
34. Go Y, Chintala SK, Mohanam S, Gokaslan Z, Venkaiaj B, Bjerkvig R, Oka K, Nicolson GL, Sawaya R, Rao JS. Inhibition of in vivo tumorigenicity and invasiveness of a human glioblastoma cell line transfected with antisense uPAR vectors. Clin Exp Metastasis 1997;15:440-6.
35. Kufe DW, Advani S, Weichselbaum R. Principles of gene therapy. In: Bast RC, Kufe DW, Pollock RE, Weichselbaum R, Holland JF, Frei E, eds. Cancer medicine e.5. Hamilton, Ontario: BC Decker, Inc., 2000. 876-89.